2. Janni W, Alba E, Bachelot T, Diab S, Gil-Gil M, Beck TJ, et al. First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial. Breast Cancer Res Treat. 2018;169:469-79. Here, ERBB2 is linked to neoplasm.